ABSTRACT
Objective: To observe the clinical efficacy and safety of injection therapy of amphotericin B combined with autologous serum in the treatment of fungal corneal ulcer
Study Design: An experimental study
Place and Duration Of Study: Department of Ophthalmology, Jinan Second People's Hospital, Shandong Province, China, from July 2013 to June 2017
Methodology: Patients diagnosed with monocular fungal corneal ulcer were divided randomly into observation group and control group, 48 cases in each group. Control group was treated with amphotericin B alone. Observation group was treated with autologous serum injection on the basis of the control group treatment. The improvement time of clinical symptoms such as hypopyon, corneal ulcer, foreign body sensation and photophobia were observed in two groups. The clinical efficacy and adverse reactions were compared between the two groups
Results: The total effective rate of the observation group was higher than that of the control group [p=0.011]. After treatment, the improvement time of the symptoms such as hypopyon, corneal ulcer, foreign body sensation, and photophobia was shorter in the observation group than the control group [all p <0.001]. There was no significant difference in adverse reaction rate between the two groups [p=0.557]
Conclusion: Injection therapy of amphotericin B combined with autologous serum has significant efficacy for fungal corneal ulcer, which can effectively improve the clinical symptoms with fewer adverse reactions and safe and reliable results, thus worthy of promotion
ABSTRACT
With the popularization and application of antiseptic drugs, the abuse of antiseptic drugs and various un reasonable applications have also become a serious medical problem. The prescriptions of antibiotics in or hospital were randomly selected for statistical analysis. Further, we analyzed the vaious situations of the use of antibiotics in outpatient department, and calculated the DDDs of different drugs based on the defined daily dose [DDD]. The results showed that there were 403 unreasonable prescriptions, accounting for 24.9% of the drug prescriptions. The main problem of irrational prescriptions were unsuitable drugs, non indications and improper frequency of adminstration, which accounted for 27.1%, 21.3% and 18.3%. It is suggested that the quality department of the hospital should strengthen the special training for rational use of antimicrobial agents, intervene in time and effectively, and gradually change post evaluation into prevention intervention in advance
ABSTRACT
BACKGROUND:Pathogenesis of Parkinson’s disease is not completely understood, and there is yet no effective therapy that can prevent the neurodegenerative process of the disease fundamentaly. OBJECTIVE:To explore the effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on lactacystin-induced Parkinson’s disease dopaminergic PC12 cel apoptosis and its molecular mechanism. METHODS: Under induction by nerve growth factors, PC12 cels differentiated into dopaminergic neurons, and then were treated with different concentrations of lactacystin for different time. When the cel survival rate was about 50%,the concentration and action time oflactacystin were selected to establish cel models of Parkinson’s disease. In the study, there were control group, lactacystin group, PACAP1-27 group (intervention group 1) and PACAP1-27+PACAP6-27 co-intervention group (intervention group 2). Changes of cel morphology were observed under inverted microscope; cel viability was detected with MTT method; the expression of endoplasmic reticulum stress specific protein caspase-12 was detected by western blot. Then the action of PACAP1-27 and PACAP6-27 to the cytoxicity of lactacystin was observed. RESULTS AND CONCLUSION: With different concentrations and action time of lactacystin, the viability of PC12 cels presented a concentration- and time-dependent decline. When the lactacystin at 20μmol/L acted for 24 hours, the cel viability was declined by about 50%. Under same conditions of lactacystin concentration and action time (20 μmol/L, 24 hours), the cels in the lactacystin group appeared to have damaged changes, declined cel viability, and increased caspase-12 activity in comparison with the control group (P< 0.01). Compared with the lactacystin group, the cel damage was relieved and cel viability was increased significantly in the intervention group 1 as wel as the expression of caspase-12 was decreased (P < 0.01). Experimental findings in the intervention group 2 were similar to those in the lactacystin group. These results suggest that lactacystin, an ubiquitin proteasome inhibitor, can lead to cel damage; PACAP1-27 plays a protective role by regulating the above-mentioned signal pathway. As one PACAP1-27 receptor antagonist, PACAP6-27 can attenuate this effect of PACAP1-27.